OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
A Trial of Centanafadine Efficacy and Safety in Adults With Attention-deficit/Hyperactivity Disorder and Comorbid Anxiety
- Conditions
- ADHDAnxiety, Generalized Anxiety, Social Anxiety Disorder
- Interventions
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Target Recruit Count
- 308
- Registration Number
- NCT06973577
- Locations
- 🇺🇸
Clinical Research Site #017 - Harmonex Neuroscience Research, Dothan, Alabama, United States
🇺🇸Clinical Research Site #011 - NRC Research Institute, Orange, California, United States
🇺🇸Clinical Research Site #005 - Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
- Conditions
- Sjogren Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Target Recruit Count
- 80
- Registration Number
- NCT06928142
- Locations
- 🇺🇸
Medvin Clinical Research - Riverside, Riverside, California, United States
🇺🇸Medvin Clinical Research - Tujunga, Tujunga, California, United States
🇺🇸Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States
A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart Failure
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-27
- Target Recruit Count
- 264
- Registration Number
- NCT06795399
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-05-18
- Target Recruit Count
- 522
- Registration Number
- NCT06894212
- Locations
- 🇺🇸
Synergy San Diego Site #128, Lemon Grove, California, United States
🇺🇸Pillar Clinical Research LLC - Bentonville Site # 145, Bentonville, Arkansas, United States
🇺🇸Pillar Clinical Research (Little Rock AR) Site #153, Little Rock, Arkansas, United States
A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
- Conditions
- Systemic Lupus Erythematosus (SLE)Alopecia Areata (AA)Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
- Interventions
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-04-11
- Target Recruit Count
- 30
- Registration Number
- NCT06799520
- Locations
- 🇲🇩
Visterra Investigational Site, Chisinau, Moldova, Republic of
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2025-04-06
- Target Recruit Count
- 25
- Registration Number
- NCT06740526
- Locations
- 🇺🇸
Clinical Research Site 330, Denver, Colorado, United States
🇺🇸Clinical Research Site 369, Boston, Massachusetts, United States
🇺🇸Clinical Research Site 374, Dakota Dunes, South Dakota, United States
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
- Conditions
- Mental DisorderSchizophreniaMajor Depressive DisorderBipolar I Disorder
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 54
- Registration Number
- NCT06372210
- Locations
- 🇺🇸
Research site, Garden Grove, California, United States
A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 60
- Registration Number
- NCT05848700
- Locations
- 🇺🇸
Woodland International Research Group, LLC, Little Rock, Arkansas, United States
🇺🇸Neuro-Behavioral Clinical Research, Inc, North Canton, Ohio, United States
🇺🇸Pillar Clinical Research, LLC, Richardson, Texas, United States
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2025-04-11
- Target Recruit Count
- 434
- Registration Number
- NCT05729373
- Locations
- 🇺🇸
American Medical Research, Inc., Warrenville, Illinois, United States
🇺🇸Copley Clinical, Boston, Massachusetts, United States
🇺🇸Boston Clinical Trials, Boston, Massachusetts, United States
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2025-04-10
- Target Recruit Count
- 101
- Registration Number
- NCT05628103
- Locations
- 🇺🇸
Clinical Innovations, Inc, Riverside, California, United States
🇺🇸California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC), San Diego, California, United States
🇺🇸Cenexel CNS Research, Torrance, California, United States